Healius Limited
ASX: HLS
Pathology volumes rebound but impairments drag pathology giant’s turnaround.
(Source: TradingView) 3-Month Performance Profile of HLS on a DTF compared to S&P/ASX 200 (XJO).
Healius Limited generated TTM revenue of $1.34 billion, down slightly yet buoyed by operational cashflow of $285 million in FY25. Heavy losses of $563 million stem from impairments and r
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
